Background
Quality indicator – development and validation methods
Quality indicators - key characteristics
Methods
Data source
Search terms
Search | Query | Items found |
---|---|---|
#71 | Search #66 AND #70 | 21 |
#70 | Search #67 OR #68 OR #69 | 144142 |
#69 | Search HIV/AIDS[Title/Abstract] | 17246 |
#68 | Search AIDS[MeSH Terms] | 70455 |
#67 | Search HIV [MeSH Terms] | 73266 |
#66 | Search #59 AND #62 AND #65 | 6914 |
#65 | Search #63 OR #64 | 11513 |
#64 | Search Quality Indicators [Title/Abstract] | 2617 |
#63 | Search Quality Indicators, Healthcare [MeSH Terms] | 10006 |
#62 | Search #60 NOT # 61 | 15517434 |
#61 | Search Human [MeSH Terms] | 12128326 |
#60 | Search Animal [MeSH Terms] | 15794808 |
#59 | Search #31 OR #58 | 6259659 |
#58 | Search #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40 OR #41 OR #42 OR #43 OR #44 OR #46 OR #47 OR #48 OR #49 OR #50 OR #51 OR #52 OR #53 OR #54 OR #55 OR #56 OR #57 | 5638100 |
#57 | Search Outcome Assessment (Health Care)[MeSH Terms] | 64 |
#56 | Search Outcome Assessment (Health Care) | 116277 |
#55 | Search Validation Studies [Publication Type] | 54533 |
#54 | Search Evaluation Studies [Publication Type] | 162083 |
#53 | Search Case Reports [Publication Type] | 1566659 |
#52 | Search Commission on Professional and Hospital Activities[MeSH Terms] | 206 |
#51 | Search Commission on Professional and Hospital Activities | 282 |
#50 | Search Models, Theoretical[MeSH Terms] | 1073230 |
#49 | Search Pilot Projects[Title/Abstract] | 453 |
#48 | Search Pilot Projects[MeSH Terms] | 69739 |
#47 | Search Research[Title/Abstract] | 689721 |
#46 | Search Research[MeSH Terms] | 394473 |
#45 | Search Statistics as Topic[MeSH Terms] | 1664889 |
#44 | Search Statistics as Topic | 1695673 |
#43 | Search Validation Studies as Topic[MeSH Terms] | 913 |
#42 | Search Validation Studies as Topic | 6755 |
#41 | Search Prospective Studies[Title/Abstract] | 17555 |
#40 | Search Prospective Studies[MeSH Terms] | 312410 |
#39 | Search Intervention Studies[Title/Abstract] | 4683 |
#38 | Search Intervention Studies[MeSH Terms] | 5150 |
#37 | Search Twin Studies as Topic[MeSH Terms] | 1360 |
#36 | Search Twin Studies as Topic | 1784 |
#35 | Search Evaluation Studies as Topic[MeSH Terms] | 895895 |
#34 | Search Evaluation Studies as Topic | 906192 |
#33 | Search Feasibility Studies[Title/Abstract] | 535 |
#32 | Search Feasibility Studies[MeSH Terms] | 35041 |
#31 | Search #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29 OR #30 | 1509215 |
#30 | Search Longitudinal Studies[Title/Abstract] | 9116 |
#29 | Search Longitudinal Studies[MeSH Terms] | 757612 |
#28 | Search Retrospective Studies[Title/Abstract] | 4389 |
#27 | Search Retrospective Studies[MeSH Terms] | 407740 |
#26 | Search Sampling Studies[Title/Abstract] | 126 |
#25 | Search Sampling Studies[MeSH Terms] | 18424 |
#24 | Search Time and Motion Studies[Title/Abstract] | 75 |
#23 | Search Time and Motion Studies[MeSH Terms] | 3137 |
#22 | Search Multicenter Studies as Topic[MeSH Terms] | 14178 |
#21 | Search Multicenter Studies as Topic | 20139 |
#20 | Search Genetic Association Studies[Title/Abstract] | 1533 |
#19 | Search Genetic Association Studies[MeSH Terms] | 10125 |
#18 | Search Seroepidemiologic Studies[Title/Abstract] | 193 |
#17 | Search Seroepidemiologic Studies[MeSH Terms] | 15564 |
#16 | Search Follow-Up Studies[Title/Abstract] | 8404 |
#15 | Search Follow-Up Studies[MeSH Terms] | 438403 |
#14 | Search Cross-Over Studies[Title/Abstract] | 284 |
#13 | Search Cross-Over Studies[MeSH Terms] | 29156 |
#12 | Search Organizational Case Studies[Title/Abstract] | 5 |
#11 | Search Organizational Case Studies[MeSH Terms] | 8339 |
#10 | Search Cross-Sectional Studies[Title/Abstract] | 3917 |
#9 | Search Cross-Sectional Studies[MeSH Terms] | 136893 |
#8 | Search Epidemiologic Studies[Title/Abstract] | 13538 |
#7 | Search Epidemiologic Studies[MeSH Terms] | 1388630 |
#6 | Search Cohort Studies[Title/Abstract] | 8010 |
#5 | Search Cohort Studies[MeSH Terms] | 1155017 |
#4 | Search Case–control Studies[Title/Abstract] | 8277 |
#3 | Search Case–control Studies [MeSH Terms] | 542455 |
#2 | Search observational study[Title/Abstract] | 24606 |
#1 | Search observational studies | 40232 |
Inclusion and exclusion criteria
Study selection
Data collection processes
Data analysis
Results
Study selection
Web HIV/AIDS quality indicators search
Studies characteristics
Author | year | Country | Study design | Objective | No. of clinical care indicators | Selection criteria |
---|---|---|---|---|---|---|
1989, 1997 | USA | Retrospective cohort | To study patients whose episode of care for pneumocystis pneumonia began on the date of hospital admission, and examine outcomes and processes of care limited to the patient portion of the care episode. | 20, 11 | Undefined | |
Wu et al. [23] | 2000 | USA | Review | To review concepts related to quality of care | 17 | Expert panel |
Asch et al. [24] | 2004 | USA | Cross-Sectional Study | To evaluate HIV quality of care using a symptom-based, patient-centered framework. | 12 | Expert panel |
Salomon et al. [25] | 2005 | USA | Cohort study | To assess the impact of patient volume on the quality of care received by AIDS patients within a state’s Medicaid managed system. | 15 | Guidelines |
Wilson at al. [26] | 2007 | USA | Cross-Sectional Study | To determine whether a selected set of indicators can represent a single overall quality construct. | 8 | Guidelines |
UNGASS Indicator registry [22] | 2008 | USA | Project | To be a central repository of information on indicators used to track the AIDS epidemic and the national, regional and global response. | 9 | Guidelines and Expert panel |
Alemayehu et al. [29] | 2009 | Ethiopia | Cross-Sectional Study | To assess the quality of clinical care provided to patients with HIV in Felege Hiwot Referral Hospital. | 14 | Guidelines and Expert panel |
Horberg et al. [27] | 2010 | USA | Project | To establish a single set of aligned HIV quality measures for care processes and intermediate outcomes for external accountability and individual quality improvement. | 17 | Guidelines and Expert panel |
Hoskins et al. [32] | 2010 | Malawi | Conceptual modeling | To discuss the challenges of monitoring the progress of the treated population in low-income countries by describing the lack of consensus on indicators, and the burden associated with compiling them. | 5 | Guidelines and Expert panel |
von Wichmann et al. [30] | 2010 | Spain | Project | To design the present quality of care indicators for persons with HIV/AIDS. | 25 | Expert panel |
Korthuis et al. [28] | 2011 | USA | Observational cohort | To examine the impact of buprenorphine/naloxone (bup/nx) treatment on quality of HIV care in a multisite cohort of patients with coexisting opioid dependence and HIV infection. | 16 | Guidelines and Expert panel |
Thanprasertsuk et al. [31] | 2012 | Thailand | Program evaluation | To report experience of HIVQUAL-T implementation in Thailand. | 14 | Guidelines |
Quality indicators
no. | Name | Type | Quality | American HIV treatment guidelines | European AIDS guidelines | Reference |
---|---|---|---|---|---|---|
A. Baseline evaluation | ||||||
1 | CD4 cell count measurement | P | S | + | + | |
2 | Appropriate viral load test timing | P | S | + | + | |
3 | Renal basic assessment (Creatinine, Blood urea nitrogen, ) | P | G | + | + | |
4 | Complete blood count | P | G | + | + | |
5 | Chemistry analysis (Serum LDH , Sodium, Venous bicarbonate, Hypoxemia ratio, Serum albumin) | P | G | + | - | [24] |
6 | Proportion of patients with CD4 count greater than 200 cells/ul | O | S | + | + | |
7 | Bilirubin | O | G | + | + | [24] |
8 | Admission body mass index | O | G | - | + | [24] |
9 | Ask about loss of appetite | P | G | - | + | [24] |
10 | Monitor patient’s weight | P | G | - | + | |
11 | CNS change | O | G | - | + | [21] |
12 | Complicated cough | O | G | - | - | [24] |
13 | Diarrhea | O | G | - | - | [24] |
14 | Heart rate | O | G | - | + | [24] |
15 | Rales | O | G | - | - | [20] |
16 | Respiratory rate | O | G | - | - | [21] |
17 | Lung examination | P | G | + | + | [24] |
18 | ECG performed in patients on methadone | P | S | - | + | [31] |
19 | Cardiovascular risk assessment | P | G | - | + | [31] |
B. Screening | ||||||
20 | Cervical cancer screening (basis and follow up) | P | G | + | + | |
21 | Hepatitis C screening (basis and follow up) | P | G | + | + | |
22 | Hepatitis B testing ever (basis and follow up) | P | G | + | + | |
23 | Tuberculosis screening | P | G | + | + | |
24 | Gonorrhea/chlamydia screening (at least once) | P | S | - | + | |
25 | Syphilis screening (annually) | P | S | - | + | |
26 | Injection drug use screening (annually) | P | G | - | + | |
27 | High-risk sexual behavior screening (annually) | P | G | - | + | |
28 | Papanicolau test in last year (for women only) | P | G | - | + | |
C. Immunization | ||||||
29 | Pneumococcal vaccine in previous 6 months if CD4 >200 | P | G | - | + | |
30 | Influenza vaccination (annually) | P | G | - | + | |
31 | Hepatitis B vaccination first dose received (if appropriate) | P | G | + | + | |
32 | Hepatitis A vaccination | P | G | + | + | |
D. Prophylaxis (patients with <200 lymphocyte CD4) | ||||||
33 | MAC prophylaxis | P | G | - | - | |
34 | PCP (pneumocystis jiroveci pneumonia) prophylaxis | P | G | - | - | |
35 | Toxoplasmosis prophylaxis | P | G | - | - | |
36 | TB prophylaxis if reactive PPD | P | G | + | - | [25] |
37 | Cryptococcosis prophylaxis for patients with CD4 <100 cells/ul | P | G | - | - | [30] |
E. HIV Monitoring | ||||||
38 | Non-detectable HIV viral load at 48 treatment weeks | O | S | + | + | |
39 | Proportion of patients who received their fist-time CD4 count within 2 weeks after first HIV clinic visit | P | S | - | - | |
40 | Proportion of patients eligible for ART who are currently on ART | P | S | + | + | [29] |
41 | Proportion of patients on ART for whom adherence is measured on last three visits | P | S | - | - | |
42 | Proportion of patients on NVP who had LFT at least once within 1 month after initiation of NVP-based ART | P | S | - | - | [29] |
43 | Proportion of patients with previous ARV regimen change for whom reason for change in regime is documented | P | S | + | + | |
44 | Proportion of patients on ARV with at least 95% (good) reported adherence on last visit | O | S | + | + | |
45 | Achieving maximal viral control if prescribed ART | O | S | + | + | [27] |
46 | Achieving maximal viral control if prescribed ART or treatment plan documentation if maximal viral control not achieved. | O | S | + | + | [27] |
47 | proportion of patients with continued care | P | G | + | + | |
48 | Visits in three quarters | P | G | + | - | |
49 | HIV counseling and test offered | P | S | + | + | |
50 | Length of stay in hospital | P | G | - | - | [20] |
51 | Loss of follow up | P | G | + | - | |
52 | Percent HIV/AIDS hospital mortality | O | S | - | - | [20] |
53 | HIV prevalence among pregnant women | P | S | + | + | [22] |
F. Therapy | ||||||
54 | Appropriately prescribed ART | P | S | + | + | |
55 | Proportion of patients on cotrimoxazole prophylaxis with at least 95% reported adherence on last visit | P | S | - | - | |
56 | Proportion of patients whose CD4 count is <350 cell/ul who are currently on cotrimoxazole prophylactic therapy | P | S | - | - | [29] |
57 | In patients with at most CD4 count <200 cells/microliter Prescribe an antibiotic or admit the patient to the hospital | P | S | - | - | [24] |
58 | Proportions of patients on ART who are started on ART within 2 weeks after clinical eligibility is confirmed | P | S | + | + | [29] |
59 | Proportion of either bedridden or ambulatory patients who have improvement in functional status | O | S | - | + | [29] |
60 | Proportion of HIV-positive clients given treatment for latent TB infection | P | S | + | + | |
61 | Proportion of HIV-positive registered TB patients given ART during TB treatment | P | S | + | + | [22] |
62 | Percent of HIV-positive patients in HIV care or treatment (pre-ART or ART) who started TB treatment | P | S | + | + | |
63 | Patient with HIV receiving Hepatitis C treatment | P | G | + | + | [31] |
64 | Co-management of Tuberculosis and HIV Treatment | P | S | + | + | [22] |
65 | Number of HIV-positive pregnant women who received antiretroviral to reduce risk of mother-to-child-transmission | P | S | + | + | [22] |
HIV/AIDS quality indicators applicability
Selection and validation methods
no. | Name |
---|---|
A. Baseline evaluation | |
1 | CD4 cell count measurement |
2 | Appropriate viral load test timing |
4 | Complete blood count |
6 | Proportion of patients with CD4 count greater than 200 cells/ul |
B. Screening | |
20 | Cervical cancer screening (basis and follow up) |
21 | Hepatitis C screening (basis and follow up) |
22 | Hepatitis B testing ever (basis and follow up) |
23 | Tuberculosis screening |
24 | Gonorrhea/chlamydia screening (at least once) |
25 | Syphilis screening (annually) |
27 | High-risk sexual behavior screening (annually) |
28 | Papanicolau test in last year (for women only) |
C. Immunization | |
31 | Hepatitis B vaccination first dose received (if appropriate) |
34 | PCP (pneumocystis jiroveci pneumonia) prophylaxis |
E. HIV Monitoring | |
38 | Non-detectable HIV viral load at 48 treatment weeks |
43 | Proportion of patients with previous ARV regimen change for whom reason for change in regime is documented |
44 | Proportion of patients on ARV with at least 95% (good) reported adherence on last visit |
47 | proportion of patients with continued care |
49 | HIV counseling and test offered |
F. Therapy | |
54 | Appropriately prescribed ART |
55 | Proportion of patients on cotrimoxazole prophylaxis with at least 95% reported adherence on last visit |
60 | Proportion of HIV-positive clients given treatment for latent TB infection |
62 | Percent of HIV-positive patients in HIV care or treatment (pre-ART or ART) who started TB treatment |